DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020-Reference-Cited by-同舟云学术

DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020

Published:2021-07-21 Issue:6 Volume:22 Page:891-900
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Jedlowski Patrick M.,Jedlowski Mahdieh F.,Fazel Maryam T.

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-021-00625-4.pdf

Reference24 articles.

1. Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol. 2007;33(1–2):67–77.

2. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320–32.

3. Nishie W. Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII. J Dermatol Sci. 2014;73(3):179–86.

4. Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol. 2019;10:1238.

5. Lee SG, Lee HJ, Yoon MS, Kim DH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol. 2019;155(2):172–7.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Retrospective Comparison of Diagnostic Tools of Bullous Pemphigoid for Elderly Patients;Journal of Cutaneous Medicine and Surgery;2024-08-06

2. Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms;Expert Opinion on Drug Safety;2024-04-23

3. Mechanistic Study of Novel Dipeptidyl Peptidase IV Inhibitory Peptides from Goat’s Milk Based on Peptidomics and In Silico Analysis;Foods;2024-04-14

4. Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients;Acta Dermato-Venereologica;2024-04-04

5. Proteomic changes related to actin cytoskeleton function in the skin of vildagliptin-treated mice;Journal of Dermatological Science;2024-03